# Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

> **NCT03386214** · PHASE1 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 8 (actual)

## Conditions studied

- Myelofibroses

## Interventions

- **DRUG:** Pevonedistat
- **DRUG:** Ruxolitinib
- **PROCEDURE:** Peripheral blood draw
- **PROCEDURE:** Skin biopsy

## Key facts

- **NCT ID:** NCT03386214
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-23
- **Primary completion:** 2021-09-12
- **Final completion:** 2021-10-04
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Sponsor stopped development of pevonedistat
- **Last updated:** 2022-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03386214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03386214, "Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03386214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*